December 12th 2024
Join Dermatology Times’ quarterly editor in chief Shanna Miranti, MPAS, PA-C, in a look back at acne milestones in 2024 such as topical clindamycin, adapalene, and benzoyl peroxide gel (Cabtreo).
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Spironolactone efficacy may be similar to oral antibiotic Tx
November 19th 2019Several retrospective analyses indicate spironolactone may have similar efficacy to oral antibiotics in the treatment of acne in women. Underuse of this off-label treatment option may be due to lack of efficacy evidence. The two options should be directly evaluated in future studies to guide practice.
40 years of dermatology breakthroughs at a glance
October 15th 2019With 4 decades of dermatology advances, we asked the very dermatologist experts who we often contact to help us to report on the milestones to weigh in on what they think have made the most difference in theirs and their patients’ lives.
FDA accepts new drug application for tazarotene lotion
August 19th 2019The U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) for Ortho Dermatologics’ novel tazarotene O.045% lotion (IDP-123) with a PDUFA action date of Dec. 22, 2019, according a recent announcement from the company.
Acne treatment alternatives to know
July 3rd 2019It’s no secret that antibiotics have been successful in controlling most acne cases, but the need to limit antibiotic use means acne treatment protocols are starting to shift. William James, M.D. emphasizes two alternatives dermatologists should turn to when treating patients with acne.
Current thinking on acne management
June 4th 2019Traditional treatments remain important parts of the dermatologist's armamentarium for acne management, but other drugs have begun to play a role, too. Meanwhile, research is offering new insight into the causes of acne. Stay up to date on the latest insight into acne's pathogenesis, evaluation and treatment. Participate in this forum.